A New Paradigm for Aptamer Therapeutic AS1411 Action: Uptake by Macropinocytosis and Its Stimulation by a Nucleolin-Dependent Mechanism
- 31 October 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (21), 8617-8629
- https://doi.org/10.1158/0008-5472.can-10-0920
Abstract
AS1411 is a first-in-class anticancer agent, currently in phase II clinical trials. It is a quadruplex-forming oligodeoxynucleotide that binds to nucleolin as an aptamer, but its mechanism of action is not completely understood. Mechanistic insights could lead to clinically useful markers for AS1411 response and to novel targeted therapies. Previously, we proposed a model where cell surface nucleolin serves as the receptor for AS1411, leading to selective uptake in cancer cells. Here, we compare uptake of fluorophore-labeled AS1411 (FL-AS1411) in DU145 prostate cancer cells (sensitive to AS1411) and Hs27 nonmalignant skin fibroblasts (resistant to AS1411). Uptake of FL-AS1411 occurred by endocytosis in both cell types and was much more efficient than an inactive, nonquadruplex oligonucleotide. Unexpectedly, uptake of FL-AS1411 was lower in cancer cells compared with Hs27 cells. However, the mechanism of uptake was different, occurring by macropinocytosis in cancer cells, but by a nonmacropinocytic pathway in Hs27 cells. Additionally, treatment of various cancer cells with AS1411 caused hyperstimulation of macropinocytosis, provoking an increase in its own uptake, whereas no stimulation was observed for nonmalignant cells. Nucleolin was not required for initial FL-AS1411 uptake in DU145 cells but was necessary for induced macropinocytosis and FL-AS1411 uptake at later times. Our results are inconsistent with the previous mechanistic model but confirm that nucleolin plays a role in mediating AS1411 effects. The data suggest a new model for AS1411 action as well as a new role for nucleolin in stimulating macropinocytosis, a process with potential applications in drug delivery. Cancer Res; 70(21); 8617–29. ©2010 AACR.Keywords
Other Versions
This publication has 47 references indexed in Scilit:
- The Biological Effect of an Antisense Oligonucleotide Depends on Its Route of Endocytosis and TraffickingOligonucleotides, 2010
- Lipid-like materials for low-dose, in vivo gene silencingProceedings of the National Academy of Sciences of the United States of America, 2010
- Cancer-selective antiproliferative activity is a general property of some G-rich oligodeoxynucleotidesNucleic Acids Research, 2009
- Plasma Membrane Nucleolin Is a Receptor for the Anticancer Aptamer AS1411 in MV4-11 Leukemia CellsMolecular Pharmacology, 2009
- Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancerExperimental and Molecular Pathology, 2009
- The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer CellsCancer Research, 2008
- Quartets in G‐majorEMBO Reports, 2007
- Activated Ras induces cytoplasmic vacuolation and non-apoptotic death in glioblastoma cells via novel effector pathwaysCellular Signalling, 2007
- P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectinExperimental Cell Research, 2006
- Nucleolin is a histone chaperone with FACT-like activity and assists remodeling of nucleosomesThe EMBO Journal, 2006